Breaking: Summit therapy beat Merck's Keytruda in late-stage cancer trial

Keytruda was the top-selling drug in the world last year, bringing in $25 billion

Log In    Subscribe Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial By Jonathan Wosen and Adam Feuerstein For years, Merck's drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in billions of dollars as the top-selling drug in the world last year.   But detailed data presented today by Summit Therapeutics demonstrated that the company's experimental therapy has done what no other has done before: beat Keytruda in a head-to-head late-stage trial in lung cancer. READ MORE Looking for more breaking biotech coverage? Sign up for Adam Feuerstein's weekly newsletter sharing no-holds-barred analysis on the rapidly shifting world of biotech. In case you missed it investigation Upending a longstanding paradigm, cardiologists embrace ZIP codes, not race, to predict heart risk flu shot Trying to time your vaccines just right? There are no easy answers, but here are some factors to consider in the lab In a first, living mice are made transparent Read more Don't miss out on another STAT+ Investigation again! Unlock the world of health and medicine with a brand-new subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us